TC
CBIO

Truvestments Capital’s Crescent Biopharma CBIO Stock Holding History

Truvestments Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13
Closed -$275 – 1026
2025
Q1 		$275 Hold
13
– – ﹤0.01% 982
2024
Q4 		$326 Hold
13
– – ﹤0.01% 965
2024
Q3 		$221 Buy
+13
New +$273 ﹤0.01% 899
2024
Q2 		– Sell
-21
Closed -$6.17K – 410
2024
Q1 		$6.17K Hold
21
– – ﹤0.01% 538
2023
Q4 		$4.86K Hold
21
– – ﹤0.01% 600
2023
Q3 		$3.09K Hold
21
– – ﹤0.01% 560
2023
Q2 		$3.58K Hold
21
– – ﹤0.01% 560
2023
Q1 		$2.59K Buy
+21
New +$4.73K ﹤0.01% 561

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Truvestments Capital's CBIO Position: Q2 2025 in Review

Truvestments Capital sold out of Crescent Biopharma (CBIO) in Q2 2025, closing a stake of 13 shares — an estimated $275 sold.

Truvestments Capital first reported a position in CBIO in Q1 2023 and held it in 8 quarters. The position peaked at $6.17K in Q1 2024. 30 funds tracked by Wall St. Rank hold CBIO as of Q2 2025.

  • Truvestments Capital reported no remaining Crescent Biopharma position as of Q2 2025 after selling out during the quarter.
  • Truvestments Capital sold 13 Crescent Biopharma shares in Q2 2025, an estimated $275.
  • Truvestments Capital first reported a position in Crescent Biopharma in Q1 2023 and held it in 8 quarters.
  • Truvestments Capital's Crescent Biopharma position peaked at $6.17K in Q1 2024.
  • 30 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2025.

Based on Truvestments Capital's 13F filing for Q2 2025, filed 13 Aug 2025.